Literature DB >> 26727543

The first case report of fatal acute pulmonary dysfunction in a systemic sclerosis patient treated with rituximab.

K Nakamura1, A Yoshizaki1, T Takahashi1, R Saigusa1, T Taniguchi1, Y Asano1, W Gonoi2, M Hinata3, A Shinozaki-Ushiku3, S Sato.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26727543     DOI： 10.3109/03009742.2015.1102963

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


× No keyword cloud information.
  3 in total

1.  Risk of bleeding events among patients with systemic sclerosis and the general population in the UK: a large population-based cohort study.

Authors:  Alexander Michel; Antonio González-Pérez; María E Sáez; Luis A García Rodríguez
Journal:  Clin Rheumatol       Date:  2019-05-14       Impact factor: 2.980

2.  Serum C-X-C Chemokine Ligand 1 Levels in Patients with Systemic Sclerosis: Relationship of Clinical and Laboratory Observations to Anti-CD20 Monoclonal Antibody Administration.

Authors:  Ruriko Kawanabe; Ayumi Yoshizaki; Kazuki M Matsuda; Hirohito Kotani; Teruyoshi Hisamoto; Yuta Norimatsu; Ai Kuzumi; Takemichi Fukasawa; Satoshi Ebata; Asako Yoshizaki-Ogawa; Shinichi Sato
Journal:  Life (Basel)       Date:  2022-04-27

3.  Rituximab treatment in patients with systemic sclerosis and interstitial lung disease.

Authors:  Abdel Gaffar A Mohammed; Ammar Alshihre; Ibrahim Abdulrazag Al-Homood
Journal:  Ann Thorac Med       Date:  2017 Oct-Dec       Impact factor: 2.219
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.